Immune checkpoint inhibitors for multiple myeloma immunotherapy

被引:13
|
作者
Liu, Zhaoyun [1 ]
Xu, Xintong [1 ]
Liu, Hui [1 ]
Zhao, Xianghong [1 ]
Yang, Chun [1 ]
Fu, Rong [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin 300052, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune checkpoint; CTLA-4; TIGIT; Multiple myeloma; treatment strategy; T-LYMPHOCYTE ATTENUATOR; KIR ANTIBODY IPH2101; PHASE-I TRIAL; PD-1; BLOCKADE; DARATUMUMAB MONOTHERAPY; ANTITUMOR IMMUNITY; B-LYMPHOCYTE; PLASMA-CELLS; EXPRESSION; CANCER;
D O I
10.1186/s40164-023-00456-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closely associated with immune escape. Immune checkpoint-related therapy has attracted much attention and research in MM. However, the efficacy of those therapies need further improvements. There need more thoughts about the immune checkpoint to translate their use in clinical work. In our review, we aggregated the currently known immune checkpoints and their corresponding ligands, further more we propose various ways of potential translation applying treatment based on immune checkpoints for MM patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
    Abushukair, Hassan Mohammed
    Saeed, Anwaar
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (06) : 1210 - 1212
  • [22] Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Rilan Bai
    Zheng Lv
    Dongsheng Xu
    Jiuwei Cui
    Biomarker Research, 8
  • [23] Role of Immune Cells and Immunotherapy in Multiple Myeloma
    Radhakrishnan, Vijay
    Golla, Upendarrao
    Kudva, Avinash Kundadka
    LIFE-BASEL, 2024, 14 (04):
  • [24] Expression of Immune Checkpoint Receptors in Multiple Myeloma Patients
    Kwon, Minsuk
    Choi, Yoon Seok
    Park, Junsik
    Shin, Eui-Cheol
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [25] Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
    Abdel-Wahab, Noha
    Suarez-Almazor, Maria E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (08) : 873 - 893
  • [26] Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy
    Ohnuma, Kei
    Hatano, Ryo
    Dang, Nam H.
    Morimoto, Chikao
    MODERN RHEUMATOLOGY, 2019, 29 (05) : 721 - 732
  • [27] Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
    Cejuela, Monica
    Vethencourt, Andrea
    Pernas, Sonia
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1801 - 1819
  • [28] Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy
    Tian, Mingming
    Zhang, Si
    Tseng, Yujen
    Shen, Xizhong
    Dong, Ling
    Xue, Ruyi
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (07) : 1244 - 1256
  • [29] Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
    Catanzaro, Elena
    Beltran-Visiedo, Manuel
    Galluzzi, Lorenzo
    Krysko, Dmitri V.
    CELLULAR & MOLECULAR IMMUNOLOGY, 2025, 22 (01) : 24 - 39
  • [30] Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options
    Le Calvez, Baptiste
    Moreau, Philippe
    Touzeau, Cyrille
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (09) : 965 - 973